A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment

Tobias Niedermaier; Elizabeth Alwers; Xuechen Chen; Thomas Heisser; Michael Hoffmeister; Hermann Brenner

doi:10.1101/2022.07.22.22277924

Abstract

PURPOSE Polygenic risk scores (PRS) have been proposed and are increasingly used for risk assessment in colorectal cancer (CRC) screening. Fecal immunochemical tests (FITs) are widely recommended and used as dichotomous tests for annual or biennial CRC screening, ignoring the quantitative information on fecal hemoglobin concentration above or below the positivity threshold.

MATERIALS AND METHODS We aimed to assess and compare the ability of a single quantitative FIT and PRS to predict presence of advanced colorectal neoplasms (preclinical CRC or advanced adenoma) as a key indicator of CRC risk. A quantitative FIT (FOB Gold, Sentinel Diagnostics) was employed and a weighted PRS based on 140 common risk variants was determined among participants of screening colonoscopy in Germany. We compared areas under the curves (AUCs) of FIT and PRS for predicting presence of advanced colorectal neoplasm in the entire study population, and in subgroups defined by age, sex, family history of CRC, and history of colonoscopy.

RESULTS A total of 3,025 participants aged 50-79 years were included, thereof 523 with advanced colorectal neoplasm and 2,502 participants without neoplasm. FIT clearly outperformed PRS in predicting presence of any advanced neoplasm in the entire study population (AUC 0.721, 95%CI 0.693-0.749 versus 0.591, 95%CI 0.564-0.617, p<0.0001), in younger (50-59 years) and older (60-79 years) participants, both sexes, those with and without a family history of CRC, and those with and without a previous colonoscopy (differences in AUC between 0.110 and 0.186, p=0.03 for those with previous colonoscopy and ≤0.005 for all other subgroups).

CONCLUSION A single quantitative FIT, a low cost, easy-to-administer and universally available test, is more informative for CRC risk assessment than so far established PRS, irrespective of age, sex, family history, or history of colonoscopy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was partly funded by grants from the German Research Council (DFG, grant No. BR1704/16-1), the Federal Ministry of Education and Research (BMBF, grant no. 01GL1712), and the German Cancer Aid (No. 70113330). The funding source had no role in any aspect pertinent to the study. None of the authors has been paid to write this article by a pharmaceutical company or other agency.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics Committee of the Medical Faculty Heidelberg (178/2005) gave ethical approval for this work Ethics Committee of the responsible state physicians chamber Baden-Wuerttemberg (M118-05-f) gave ethical approval for this work. Ethics Committee of the responsible state physicians chamber Rheinland-Pfalz (837.047.06(5145)) gave ethical approval for this work. Ethics Committee of the responsible state physicians chamber Saarland (217/13) gave ethical approval for this work. Ethics Committee of the responsible state physicians chamber Hessen (MC 254/2007) gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Conflicts of Interest: The authors declare no potential conflicts of interest.
Writing assistance: none
Data availability: All data referred to in the present study are available upon reasonable request to the authors.
Funding: This study was partly funded by grants from the German Research Council (DFG, grant No. BR1704/16-1), the Federal Ministry of Education and Research (BMBF, grant no. 01GL1712), and the German Cancer Aid (No. 70113330). The funding source had no role in any aspect pertinent to the study. None of the authors has been paid to write this article by a pharmaceutical company or other agency.